A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Recruiting · Phase 2 · NCT07145918
Conditions: Schizophrenia
At a glance
- Research payments reported, 2025
- $210,155
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 268
About the trial
- Sponsor
- AbbVie
- Tested
- Emraclidine (drug), Placebo (drug)
- Dates
- Started 2025-08-04; completion 2028-02
- Results posted
- Not yet
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 268 participants will be enrolled across roughly 32 sites in the United States. Partici…
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $210,155 in research payments for this study in 2025 (9 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- George Konis, M.D. Family Medicine · Little Rock, AR
- Lev Gertsik, M.D. Psychiatry · South Pasadena, CA
- Elia E. Acevedo Diaz, M.D Psychiatry · Gaithersburg, MD
- Scott R. Bartley, M.D. Psychiatry · Dallas, TX
- David W. Brown, M.D. Psychiatry · Austin, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pillar Clinical Research LLC $181,496
- Community Clinical Research Inc $23,118
- St Louis Clinical Trials $1,440
- Community Clinical Research $1,440
- Cbh Health LLC $1,385
- Parexel International LLC $1,275
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.